Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
BENZYLPENICILLIN PROCAINE, DIHYDROSTREPTOMYCIN SULPHATE
Chanelle Pharmaceuticals Manufacturing Limited
QJ01RA01
BENZYLPENICILLIN PROCAINE, DIHYDROSTREPTOMYCIN SULPHATE
200/200 Mg/Ml
Suspension for Injection
POM
Bovine, Ovine, Porcine
Penicillins, combinations with other antibacterials
Antibacterial
Authorised
2000-08-18
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Chan Pen Strep Suspension for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, sheep, pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of infections caused by bacteria sensitive to penicillin and dihydrostreptomycin in cattle, sheep and pigs. 4.3 CONTRAINDICATIONS Not to be administered to animals known to be sensitive to penicillin. Not to be used when it is known that penicillinase-producing staphylococcus organisms are present. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Occasionally in sucking and fattening pigs administration of products containing procaine penicillin may cause a transient pyrexia, vomiting, shivering, listlessness and incoordinations. In pregnant sows and gilts a vulval discharge which could be associated with abortion has been reported. The maximum dose volume recommended at any one site for cattle is 20 ml. Each ml contains: ACTIVE SUBSTANCE Procaine Benzylpenicillin 200 mg Dihydrostreptomycin Sulphate (as dihydrostreptomycin sulphate) 200 mg EXCIPIENT Sodium formaldehyde sulfoxylate 0.432 mg Methyl Parahydroxybenzoate 1 mg HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 09/06/2015_ _CRN 7021129_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Not for use in lactating ewes producing milk for human consumption. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regiona Read the complete document